Immunohistochemical analysis of adhesion molecules and matrix metalloproteinases in malignant CNS lymphomas: a study comparing primary CNS malignant and CNS intravascular lymphomas

Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288

Hochberg FH, Baehring JM, Hochberg EP (2007) Primary CNS lymphoma. Nat Clin Pract Neurol 3:24–35

Hiraga S, Arita N, Ohnishi T, et al (1999) Rapid infusion of highdose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91:221–230

Ferry JA, Harris NL, Picker LJ, et al (1988) Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod Pathol 1:444–452

Wick MR, Mills SE (1991) Intravascular lymphomatosis: clinicopathologic features and differential diagnosis. Semin Diagn Pathol 8:91–101

Baehring JM, Henchcliffe C, Ledezma CJ, et al (2005) Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. J Neurol Neurosurg Psychiatry 76:540–544

Baehring JM, Longtine J, Hochberg FH (2003) A new approach to the diagnosis and treatment of intravascular lymphoma. J Neurooncol 61:237–248

Stefanidakis M, Koivunen E (2006) Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood 108: 1441–1450

Chu PG, Arber DA (2001) CD79: a review. Appl Immunohistochem Mol Morphol 9:97–106

Weiss LM, Arber DA, Strickler JG (1994) Nasal T-cell lymphoma. Ann Oncol 5(suppl 1):39–42

Bashir R, Coakham H, Hochberg F (1992) Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain. J Neurooncol 12:103–110

Ponzoni M, Arrigoni G, Gould VE, et al (2000) Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 31:220–226

Tews DS, Nissen A (1998) Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 18:271–284

Sood RR, Taheri S, Candelario-Jalil E, et al (2008) Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab 28:431–438

Yang Y, Estrada EY, Thompson JF, et al (2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27:697–709

Jalkanen S, Aho R, Kallajoki M, et al (1989) Lymphocyte homing receptors and adhesion molecules in intravascular malignant lymphomatosis. Int J Cancer 44:777–782

Hazar B, Polat G, Seyrek E, et al (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin’s and non-Hodgkin’s lymphoma. Int J Clin Pract 58:139–143

Sakata K, Satoh M, Someya M, et al (2004) Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer (Phila) 100:356–365